Maiwei Bio-B (02493) saw a sharp increase in revenue and gross profit in the first half of the year, and the core pipeline achieved a number of key clinical milestones

According to the Zhitong Finance App, Maiwei Bio-B (02493) announced its 2026 interim results, with revenue of about 312 million yuan, up 209.06% year on year; gross profit of about 236 million yuan, up 198.67% year on year; R&D costs about 431 million yuan, up about 10% year on year; parent company owners should account for losses of about 522 million yuan, a decrease of 5.37% year on year.

According to the announcement, the increase in revenue was mainly due to the increase in external licensing revenue of Kalexo and Disc, as well as the increase in revenue due to the increase in sales revenue of Junmaikang® pharmaceuticals.

The company has always taken innovative research and development as the core development strategy, and has built a full-cycle innovation system starting from antibody drug target verification and molecular discovery. It has three characteristic technology platforms: an antibody conjugation (ADC) drug development platform, an integrated high-efficiency antibody discovery platform, and a TCE double/three specific antibody development platform. The company has 15 key varieties in clinical research or marketing, including 11 innovative drugs and 4 biosimilar drugs, focusing on tumors and age-related diseases, such as immunology, ophthalmology, orthopedics, etc. Among them, there are 4 varieties that have already been marketed, 1 variety that is in the review stage of registration and marketing license applications for domestically produced drugs, 2 varieties in the critical phase III clinical registration stage, and other varieties in different clinical research stages. The core product, 9MW2821, has entered a critical clinical phase and obtained multiple breakthrough therapy certifications (BTD). Currently, four phase III key registered clinical trials are underway. Among them, the phase III clinical plan for urothelial carcinoma (UC) single drug and combination therapy, and cervical cancer (CC) single drug therapy is scheduled to be analyzed in 2026. It is expected that the results of this analysis will be submitted to a pre-marketing conference for the new drug. In addition, phase III clinical trials for triple-negative breast cancer (TNBC) (topoisomerase ADC treated as a single agent) and phase Ib clinical trials in the US are also being actively promoted.

Looking forward to the future, the company will accelerate the testing phase of the core product. Currently, the Nectin-4 targeted ADC product 9MW2821, which is the company's core self-developed, ranks first in the country and second in the world. It is also the world's first same-target drug to advance to stage III clinical registration of cervical cancer. Currently, the three core indications for urothelial cancer, combined immunotherapy, and cervical cancer are in the critical phase III clinical phase. The company will continue to lean R&D resources to efficiently advance various clinical studies and registration preparations. It plans to complete phase III clinical phase mid-phase analysis and subsequent marketing application communication within 2026, and strive to bring this innovative treatment with differentiated efficacy and safety advantages to the vast number of solid cancer patients in China as soon as possible.